News & Updates

MS patients on certain DMTs may have limited protection from COVID-19 vax
MS patients on certain DMTs may have limited protection from COVID-19 vax
30 May 2022 byRoshini Claire Anthony

The overall rate of hospitalization for COVID-19 is low among patients with multiple sclerosis (MS) treated with disease-modifying therapies (DMTs) who have been vaccinated against COVID-19, according to a prospective study from England. However, patients on ocrelizumab or fingolimod have elevated hospitalization rates.

MS patients on certain DMTs may have limited protection from COVID-19 vax
30 May 2022
Tuberculosis common in CKD patients
Tuberculosis common in CKD patients
27 May 2022
SARS-CoV-2 antigen tests exhibit moderate-to-high sensitivity vs RT-PCR, cultures
SARS-CoV-2 antigen tests exhibit moderate-to-high sensitivity vs RT-PCR, cultures
26 May 2022 byAudrey Abella

Home antigen tests for SARS-CoV-2 infection were moderately sensitive compared with RT-PCR* test but highly sensitive compared with viral culture in adults and children with RT-PCR-confirmed infection, a prospective study suggests.

SARS-CoV-2 antigen tests exhibit moderate-to-high sensitivity vs RT-PCR, cultures
26 May 2022